Graft Versus Host Disease (GvHD) Market to Observe Impressive Growth by 2030 | Key Companies includes – Medac, Takeda, Xenikos, CSL Behring, Syndax, Kadmon, and Others

Graft Versus Host Disease (GvHD) Market to Observe Impressive Growth by 2030 | Key Companies includes - Medac, Takeda, Xenikos, CSL Behring, Syndax, Kadmon, and Others

“Delveinsight Business Research LLP”
DelveInsight’s “Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Graft Versus Host Disease Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Graft Versus Host Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Graft Versus Host Disease: An Overview

According to the National Cancer Institute (NCI), Graft versus host disease (GvHD) is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms of GvHD include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD occurs when particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them.

Graft Versus Host Disease Market Key Facts

  • As per a study by Elgaz S. et al., (2019), aGvHD occurs in 30–50% of recipients and 14% of all patients suffer severe GvHD grades 3–4. Chronic GvHD affects 30–70% of patients receiving allo-SCT. 

  • As per a study by Jacobsohn and Vogelsang (n.d.), in the United States, approximately 5,500 patients/year can develop acute GVHD and in 2003, the incidence of grade II-IV acute GVHD was roughly 35–50%.

  • As per Orphanet, about 35%-50% of hematopoietic stem cell transplant (HSCT) recipients will develop acute Graft versus host disease (GVHD). And about 50% of patients with acute GVHD will eventually have manifestations of chronic GVHD.

Key Benefits of Graft Versus Host Disease Market Report

  • The report provides an in-depth analysis of Graft Versus Host Disease Market Size and Share till 2030 in the seven major markets.

  • The report will help in developing business strategies by understanding the Graft Versus Host Disease Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.

  • It covers Graft Versus Host Disease current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

  • The report provides a detailed assessment of the Graft Versus Host Disease market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Graft Versus Host Disease (GvHD) Market 

The Graft Versus Host Disease (GvHD) market size is expected to increase during the forecast period owing to the launch of upcoming therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Graft Versus Host Disease market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Graft Versus Host Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Get FREE sample copy at:

 Graft Versus Host Disease Epidemiology

The epidemiology section covers insights about the historical and current Graft Versus Host Disease patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Graft Versus Host Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graft Versus Host Disease market or expected to get launched in the market during the study period. The analysis covers Graft Versus Host Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Graft Versus Host Disease Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

The dynamics of the Graft versus Host Disease market is anticipated to change in the coming years owing to the rise in healthcare spending across the world.

Key Companies in the Graft Versus Host Disease (GvHD) Market includes:

  • Medac 

  • Takeda 

  • Xenikos 

  • MaaT Pharma 

  • CSL Behring 

  • Syndax Pharmaceutical

  • Kadmon Corporation

  • Mesoblast/Osiris Therapeutics 

  • Regimmune Corporation 

  • OncoImmune/Merck (MSD) 

  • ElsaLys Biotech/Mediolanum Farmaceutici

And many others.

Graft Versus Host Disease (GvHD) Therapies covered in the report includes:

  • MaaT013

  • RGI-2001

  • MK-7110 (CD24Fc)

  • T-Guard

  • CSL 964 AAT (Zemaira)

  • Obnitix (MC0518)

  • KD025 (Belumosudil)

  • Leukotac (Inolimomab)

  • Axatilimab (SNDX-6532)

  • Entyvio (Vedolizumab;MLN0002)

  • Ryoncil (Remestemcel-L; Prochymal)

And many others.

Apart from the drugs mentioned above, there are many other companies trying their hands in this area to find either the best prophylaxis or curative option in order to provide lifetime relief to the patient pool suffering or who might suffer from GvHD in the future. It will be interesting to observe how dynamically the market changes once these emerging candidates get approved in the market.

Request for Sample @ Graft Versus Host Disease Therapeutics Market Assessment

Table of Content

1. Key Insights

2. Executive Summary 

3. Graft Versus Host Disease Competitive Intelligence Analysis

4. Graft Versus Host Disease Market Overview at a Glance

5. Graft Versus Host Disease Disease Background and Overview

6. Graft Versus Host Disease Patient Journey

7. Graft Versus Host Disease Epidemiology and Patient Population

8. Graft Versus Host Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Graft Versus Host Disease Unmet Needs

10. Key Endpoints of Graft Versus Host Disease Treatment

11. Graft Versus Host Disease Marketed Products

12. Graft Versus Host Disease Emerging Therapies

13. Graft Versus Host Disease Seven Major Market Analysis

14. Attribute Analysis

15. Graft Versus Host Disease Market Outlook (7 major markets)

16. Graft Versus Host Disease Access and Reimbursement Overview

17. KOL Views on the Graft Versus Host Disease Market.

18. Graft Versus Host Disease Market Drivers

19. Graft Versus Host Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Latest Reports By DelveInsight

Graft Versus Host Disease (GvHD) Pipeline

Graft versus host disease (GvHD) Pipeline Insight, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Graft versus host disease (GvHD) market.

Trending Healthcare Blog – 

Iron Deficiency Anemia Therapeutics Market Outlook

As per DelveInsight, the Iron Deficiency Market is expected to witness growth at a CAGR of 3.7% in the 7MM during the forecast period (2021-30). To bridge the gap between available therapies and demand for better patient outcomes, key pharma, and biotech companies such as Akebia Therapeutics (Keryx Pharmaceuticals), Torii Pharmaceutical, Shield Therapeutics, Norgine, and others are working to enhance the treatment scenario with novel therapies. Read More: Iron Deficiency Anemia Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States